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While glioblastoma multiforme (GBM) is the most common adult malignant brain tumor,
GBMs in childhood represent less than 10% of pediatric malignant brain tumors and
are phenotypically and molecularly distinct from adult GBMs. Similar to adult patients,
outcomes for children with high-grade gliomas (HGGs) remain poor. Furthermore,
the signiﬁcant morbidity and mortality yielded by pediatric GBM is compounded by
neurotoxicity for the developing brain caused by current therapies. Poor outcomes have
been attributed to a subpopulation of chemotherapy and radiotherapy resistant cells,
termed “glioma stem cells” (GSCs), “glioma progenitor cells,” or “glioma-initiating cells,”
which have the ability to initiate and maintain the tumor and to repopulate the recurring
tumor after conventional therapy. Future innovative therapies for pediatric HGG must
be able to eradicate these therapy-resistant GSCs. Oncolytic herpes simplex viruses
(oHSV), genetically engineered to be safe for normal cells and to express diverse foreign
anti-tumor therapeutic genes, have been demonstrated in preclinical studies to infect
and kill GSCs and tumor cells equally while sparing normal brain cells. In this review, we
discuss the unique aspects of pediatric GSCs, including markers to identify them, the
microenvironment they reside in, signaling pathways that regulate them, mechanisms
of cellular resistance, and approaches to target GSCs, with a focus on the promising
therapeutic, genetically engineered oHSV.
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INTRODUCTION
Glioblastomamultiforme (GBM), classiﬁed as a high-grademalig-
nant glioma, occurs in both adults and children. Although adult
and childhood GBM are similarly heterogeneous tumors that
develop from glial origin, signiﬁcant differences exist between the
tumors. While GBM is the most common malignant brain tumor
in adults, it represents less than 10% of pediatric malignant brain
tumors (Ries et al., 2006). Pediatric GBM typically arise de novo as
a primary tumorwhereas adult GBMmay develop from themalig-
nant progression of a low-grade glioma. Additionally, childhood
high-grade gliomas (HGGs) can arise in the brainstem or spinal
cord, which rarely occurs in adults. Despite multimodality therapy
including surgery, chemotherapy, and radiotherapy, outcomes for
both adults and children with HGGs remain poor with overall sur-
vival rates <20% (Massimino et al., 2005; Stupp et al., 2005; Song
et al., 2010; Wolff et al., 2010; Cohen et al., 2011). Pediatric GBM
patients have a marginal survival advantage compared to adults,
however current therapies such as radiation can cause severe neu-
rotoxicity to the developing brain that can further complicate the
already signiﬁcant morbidity in children. Many of the differences
between pediatric and adult GBM may be attributed to distinct
molecular patterns.
Integrated genomic analysis identiﬁed four clinically relevant
subtypes of GBM in adults distinguished by gene aberrations such
as PDGFRα and IDH1 (proneural), EGFR (classical), and NF1
(mesenchymal; Verhaak et al., 2010). The subtypes are not as
well deﬁned in pediatric GBM where genetic proﬁling revealed
PDGFRα as the predominant focal ampliﬁcation target and gene
expression analyses indicated deregulation of PDGFRα signaling
plays an important role in tumor development (Paugh et al., 2010).
Furthermore, pediatricGBMdemonstrate decreased expression of
EGFR and reduced mutation rate of IDH1 and TP53 compared to
adult GBM, whereas other molecular markers of poor prognosis
such as MGMT overexpression and Akt activation remain simi-
lar (Pollack et al., 2001, 2006, 2010; Hegi et al., 2005; Paugh et al.,
2010; MacDonald et al., 2011).
Glioblastoma multiformes are a heterogeneous mixture of
numerous cell types, both neoplastic and non-neoplastic. Among
the vascular, tumor, immune, and other various cell types, a sub-
population of critical cells exists termed“glioma stem cells”(GSCs;
Singh et al., 2003; Galli et al., 2004). These GSCs are thought to
have stem cell properties; they are multipotent and possess the
ability to self-renew and to initiate and maintain the neoplas-
tic clone. GSCs are putatively responsible for tumor initiation,
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maintenance, metastasis, and recurrence. Whether they are true
stem cells has been debated with some preferring to call these cells
“glioma progenitor cells”– suggesting the cells are more differenti-
ated than a stem cell – or “glioma-initiating cells” which describes
their ability to initiate tumors.
The origin of these cells and the triggers that result in their
transformation are still being elucidated. GSCs,which sharemark-
ers of normal neural stem cells, have been isolated from both
pediatric low-grade gliomas (LGG) and HGGs suggesting that
pediatric GSCs may emerge from normal neural stem cells that
become mutated resulting in the loss of regulated cell division
(Thirant et al., 2011). However, the origin of some GSCs may
be a more committed cell; recent evidence suggests that even
the most differentiated neurons and glial cells can dedifferentiate
into stem-like cells and initiate gliomas (Friedmann-Morvinski
et al., 2012). This indicates that there may be multiple cells
of origin and this may result in clinical heterogeneity. Fur-
thermore, because pediatric and adult gliomas are molecularly
distinct, the initiating event resulting in a transformed GSC is
likely different in children and adults. Irrespective of their ori-
gin, these cells have been implicated in the development of
chemotherapy and radiation resistance which makes them clin-
ically signiﬁcant (Bao et al., 2006a; Eramo et al., 2006; Liu et al.,
2006). Consequently, new innovative therapies are needed to target
GSCs.
One such promising therapy is engineered oncolytic herpes
simplex virus (oHSV) which has been genetically engineered to
provide safety for normal cells but can target and kill cancer cells.
In addition, a diverse range of foreign anti-tumor therapeutic
genes can be expressed which augment the oncolytic effect and
may speciﬁcally target unique features of GSCs. In this review, we
discuss the unique aspects of pediatric GSCs, including markers
to identify them, the microenvironment they reside in, signaling
pathways that regulate them, mechanisms of cellular resistance,
and approaches to target GSCs, with a focus on the promising
therapeutic, genetically engineered oHSV.
PEDIATRIC GLIOMA STEM CELLS
MARKERS
Identifying GSCs is vitally important to study their behavior and
function and to develop targeted therapies against them. GSCs,
which share many of the characteristics of normal neural stem
cells, have been identiﬁed by cell surface proteins, cytoplasmic
and nuclear proteins, transcription factors, enzymes, and func-
tional attributes (see Table 1; Dimov et al., 2011; Friedman and
Gillespie, 2011). Hemmati et al. (2003) ﬁrst recognized that when
pediatric HGG cells were grown in culture in serum-free medium
with speciﬁc stem cell deﬁned growth factors including epider-
mal growth factor and basic ﬁbroblast growth factor, the cells
formed in clumps as spheres or“neurospheres”and expressed pro-
teins normally associated with non-transformed neural stem cells
such as CD133, the transcription factor Sox2, and the nuclear and
cytoplasmic proteins musashi-1 and bmi-1. Subsequently, CD133
(prominin-1), a transmembrane protein with uncertain biologic
function, became the most common marker used to identify can-
cer stem cells from a variety of diverse adult and pediatric solid
tumors including HGGs.
Table 1 | Markers used to identify glioma stem cells.
Attribute Marker
Cell surface proteins CD133, CD15, CD44, CXCR4, integrin alpha 6
Cytoplasmic and
nuclear proteins
Nestin, musashi-1, bmi-1
Transcription factors Sox2
Enzymes ALDH1
Functional Neurosphere formation, side population
Tumor-initiating ability
While there are an abundance of studies utilizing CD133 to
study GSCs in adult HGG models, few pediatric-speciﬁc stud-
ies exist. Shu et al. (2008) demonstrated that xenografts derived
by implanting pediatric HGG cells orthotopically in immune-
deﬁcient mice could maintain the CD133+ GSC fraction, thus
providing a useful model for studying GSCs. The CD133+ cells
formed neurospheres and displayed multi-lineage differentiation
capabilities in culture. In a pediatric GBM model, Donovan et al.
(2012) found CD133+ cells expressed a higher percentage of the
intermediate ﬁlament nestin,musashi-1, and CD15 (stage-speciﬁc
embryonic antigen 1 or SSEA-1) and had increased prolifera-
tion compared to CD133− cells. CD133 expression was directly
linked tooxygen tensionwith increased expression seen inhypoxia,
which is similar to our ﬁnding of a fourfold increase in CD133
expression in pediatric GBM xenograft cells maintained in stem
cell deﬁned medium and 1% hypoxia compared to normoxia
(Friedman et al., 2012a). They found no difference in genomic
imbalances in the CD133+ and CD133− cells which is consis-
tent with the transilience of CD133 expression observed. In an
extensive examination of pediatric brain tumor surgical speci-
mens, Thirant et al. (2011) found that tumor cells with stem-like
properties could be isolated from both pediatric LGGs and HGGs.
The cells from one LGG and several HGGs grew as neurospheres
and shared a molecular proﬁle of mesenchymal and neural stem
cells including expression of Sox2, bmi-1, and nestin, suggesting a
high level of plasticity. A majority of the cells in both the LGG and
HGGs expressed CD133 and CD15.
Other cell surface markers which have been employed as an
alternative to CD133 to identify GSCs in adult GBMs include
CD15, which has also been established as a pediatric medulloblas-
toma stem cell marker; CD44, a cell adhesion and migration
molecule; the adhesion molecule CXC chemokine receptor 4
(CXCR4); and intergrin alpha 6, the receptor for the extracellular
matrix protein laminin (Mao et al., 2009; Read et al., 2009; Anido
et al., 2010; Lathia et al., 2010; Zheng et al., 2011). Further stud-
ies are necessary to determine if these surface proteins are useful
GSC markers in pediatric HGG. A number of other non-surface
markers have been utilized to identify GSCs typically together with
a surface marker. The cytoplasmic proteins musashi-1, an RNA-
binding protein, and bmi-1, a polycomb protein, are thought to
play a role in inhibiting differentiation and promoting self-renewal
of GSCs (Okano et al., 2002; Abdouh et al., 2009). Sox2 maintains
proliferation and inhibits differentiation of neural stem cells and
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possibly GSCs (Phi et al., 2008). Nestin, an intermediate ﬁlament
found in neural stem cells and GSCs, appears to be involved in
the structural organization of cells and important in cell prolif-
eration and preventing differentiation (Michalczyk and Ziman,
2005; Dimov et al., 2011). Recently, the enzyme aldehyde dehy-
drogenase 1 (ALDH1) has been proposed as a GSC marker due to
increased neurosphere formation and maintenance of tumor cells
in an undifferentiated state with high levels of the protein (Rasper
et al., 2010). Many studies have relied on functional attributes
of cells such as the ability of cells to grow in neurospheres or
to extrude Hoechst 33342 dye to identify a side population (SP)
of cells (Wan et al., 2010). SP cells have increased expression of
members of the ATP-binding cassette (ABC) transporters which
play an important role in chemoresistance through rapid efﬂux of
chemotherapeutics.
Many problems exist with the currentmethods to identifyGSCs
(Wan et al., 2010; Friedman and Gillespie, 2011). Deﬁning and
isolating populations of cells based on surface, cytoplasmic or
nuclear markers, transcription factors, or enzymes can be chal-
lenging due to the transilient expression of some markers and the
fact that expression is on a continuum and does not appear to
be qualitatively associated with tumor cells. Thus, determining
what is a positive GSC or negative tumor cell is often subjec-
tive and may explain discrepancies seen in the literature, such
as reports of CD133− cells representing the glioma-initiating cell
population (Ogden et al., 2008;Wang et al., 2008; Chen et al., 2010;
Prestegarden et al., 2010). Deﬁning GSCs by cellular functional
attributes is problematic as well for several reasons. The neuro-
sphere assay is an in vitro cell culture phenomenon without a
clear in vivo equivalence and without a standardized protocol.
Single cells grown in serum-free medium will re-aggregate into
neurospheres, and a majority of cells in a sphere may actually
be differentiated tumor cells, making it unclear what popula-
tion of cells is actually being studied. While SP identiﬁes cells
that may have inherent chemoresistance thereby making these
cells clinically relevant, not all tumors contain a SP fraction and
SP cells do not necessarily have stem-like properties. Therefore,
new standardized methods to deﬁne, identify, isolate, and study
GSCs are needed, and due to biologic differences in adult ver-
sus pediatric HGGs, studies conducted with pediatric models are
required.
NICHE
While deﬁning GSC behavior and function is critical to designing
therapies that can target these resistant cells, equally important is
understanding the specialized microenvironment or niche where
GSC reside and are maintained and regulated. Cell-to-cell com-
munication, the extracellular matrix and tissue structure, various
secreted factors and signals, and oxygen tension all inﬂuence the
function of this poorly understood niche. GSCs are thought to
reside in both hypoxic and perivascular niches which provide
signals to GSCs that promote their maintenance and inﬂuence
their behavior (Filatova et al., 2012). Similarly, GSCs produce fac-
tors that shape the niches. It is this cellular communication that
appears to fosters tumor evolution and propagation; the crosstalk
between cells has been shown to alter the microenvironment,
such as stimulation of angiogenesis, and shape the recruitment
of various cells from endothelial cells to immune cells, which can
modulate antitumor responses, to normal neural stem cells which
may become transformed (Filatova et al., 2012). GSCs appear
to be regulated through a tight balance between inhibiting and
promoting factors driven by various growth factors, cell-to-cell
signaling and the extracellular matrix present in the perivascular
compartment which maintain homeostasis or shift GSCs toward
proliferation and differentiation (Bao et al., 2006b; Li and Neaves,
2006; Calabrese et al., 2007; Lathia et al., 2010).
A critical component of the niche and known regulator of
GSCs is hypoxia. Gliomas experience a physiologic hypoxia with
hypoxic gradients ranging from mild (10%) to moderate (2.5%)
or severe (0.1%), which marks areas of necrosis, and HGGs con-
tain more regions of moderate and severe hypoxia compared to
LGGs (Collingridge et al., 1999; Evans et al., 2004a,b). Hypoxia
supports GBM development, invasion and aggressiveness, angio-
genesis, and resistance to chemotherapy and radiation (Evans
et al., 2004a; Jensen, 2009), all features which may be due to
hypoxia’s role in promoting the GSC-phenotype. Hypoxia has
been shown to increase the pediatric GSC subpopulation and
induce pediatric GSCs to secretemarkedly elevated levels of vascu-
lar endothelial growth factor (VEGF; Bao et al., 2006b; Donovan
et al., 2012; Friedman et al., 2012a). With the secretion of VEGF,
GSCs promote endothelial cell migration and angiogenesis. Fur-
ther elucidation of the complex role of the GSC niche in pediatric
HGG is essential, so that future therapeutics can be designed to
disrupt the microenvironment and thereby target GSCs.
SIGNALING PATHWAYS
An important component of GSCs and their relationship with the
microenvironment is the balance of signaling pathways which can
further induce their stem-like properties. Normal signaling path-
ways and control mechanisms can become dysregulated through
gene ampliﬁcations resulting in overexpression of receptors or lig-
ands, or altered receptors that can initiate downstream pathways
(Prenzel et al., 2001). The embryonic signaling pathways sonic
Hedgehog (SHH), Wnt, and Notch have been shown to regu-
late normal neural stem cells and neurogenesis (Shi et al., 2008).
Although currently there are few reports implicating these path-
ways in pediatric gliomas, studies have shown that these pathways
actively promote the brain tumor stem cell-phenotype in pedi-
atric medulloblastoma and ependymoma and in adult gliomas
(Reya and Clevers, 2005; Fan et al., 2006; Shih and Holland, 2006;
Clement et al., 2007; Yang et al., 2008; Moore, 2009; Nager et al.,
2012). SHH has a critical role in the maintenance of GSCs by
regulating stemness genes and promoting tumorigenesis and pro-
liferation, and Hedgehog signaling is active in some pediatric
diffuse intrinsic pontine gliomas (DIPGs; Clement et al., 2007;
Monje et al., 2011; Takezaki et al., 2011). Inhibiting Hedgehog sig-
naling prevented tumorigenicity and GSC proliferation in HGGs
and decreased the self-renewal ability of DIPG neurospheres. The
Wnt/β-catenin pathway has been linked to GSCs and their role in
gliomagenesis and tumor proliferation and invasion (Nager et al.,
2012). Notch signaling has been shown to enhance nestin expres-
sion, promote GSC self-renewal and radioresistance, and suppress
GSC differentiation (Shih and Holland, 2006; Wang et al., 2010;
Hu et al., 2011).
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Receptor tyrosine kinases (RTKs) and other downstream path-
ways similarly have been causally linked to gliomagenesis and GSC
maintenance and proliferation. The RTK family mediates several
oncogenic growth factor pathways like EGFR and PDGFR that
have been linked to malignancy, angiogenesis, self-renewal, and
multipotency (Dimov et al., 2011). When GSCs were ﬁrst discov-
ered, Hemmati et al. (2003) established that epidermal growth
factor was a critical components in medium used to culture and
maintain GSCs. A recent study revealed that constitutively acti-
vated EGFRvIII expression and PTEN loss in murine neural stem
cells resulted in glial tumors (Li et al., 2009). The transformed
cells had increased proliferation, self-renewal ability, and CD133
expression. Jin et al. (2011) showed that EGFR signaling regulates
GSCproliferation by inducing inhibitor of differentiation 3 (ID3)-
driven cytokines. EGFR inhibitors decreased GSC neurosphere
formation. While EGFR is more commonly ampliﬁed and over-
expressed in adult gliomas, recent evidence suggests that EGFR
ampliﬁcation and EGFRvIII mutations may occur more often
in pediatric HGGs than previously recognized (Bax et al., 2009).
Downstream pathways of EGFR including phosphatidylinositol
3-kinase (PI3-K), Akt, and mTor likewise are critical regulators
of GSCs. Inhibiting both PI3-K and mTor elicited a prodifferen-
tiation effect on GSCs (Sunayama et al., 2010). Akt activation is
common in pediatric HGGs and may represent a worse prognos-
tic feature (Pollack et al., 2010). This may be due to Akt induced
activation of transporter ABCG2 (Bleau et al., 2009).
PDGF overexpression has been implicated in gliomagenesis,
and PDGFs can inhibit glial cell differentiation (Fomchenko and
Holland, 2007). The effect of PDGF is not limited to autocrine
function but also paracrine; production of PDGF by glioma cells
can recruit glial progenitor cells and other cell types which play
a key role in vasculogenesis and the tumor microenvironment
(Assanah et al., 2006; Fomchenko and Holland, 2007). PDGFRα is
overexpressed in most pediatric HGGs and gene ampliﬁcation is
seen in approximately one-third of HGGs includingDIPGs (Paugh
et al., 2010; Zarghooni et al., 2010). Further research into the role
of various signaling pathways in pediatric GSCs and the GSC
niche is needed, as these pathways represent promising treatment
targets.
RESISTANCE
A critical feature of GSCs which makes them clinically rele-
vant, irrespective of their origin, is their inherent resistance
to traditional chemotherapy and radiation. Several studies have
demonstrated resistance of pediatric GSCs to chemotherapeutic
agents like temozolomide and etoposide and to ionizing radia-
tion (Bao et al., 2006a; Hussein et al., 2011; Thirant et al., 2011).
The mechanisms proposed for the chemoresistance of pediatric
GSCs include efﬁcient DNA repair and high levels of expression
of O6-methylguainine-DNA-methyltransferase (MGMT), cellular
quiescence, and overexpression of multi-drug resistance trans-
porters. Hussein et al. (2011) demonstrated that pediatric GSC
neurospheres were able to repair DNA faster after exposure to the
topoisomerase II inhibitor etoposide than glioma cells grown as a
monolayer. Furthermore, cells grown as neurospheres were more
likely to be in G0/G1 cell cycle phase than S or G2 suggesting that
cellular quiescence may play a role.
MGMT, which removes alkyl groups from the O6 position
of guanine thereby repairing DNA damage caused by alkylating
agents like temozolomide, has been shown to be an impor-
tant prognostic variable in pediatric GBM (Donson et al., 2007).
Similar to adults, children with a methylated MGMT promoter
which silences the gene and decreases the enzyme activity have
a survival advantage compared to patients with an unmethylated
promoter. Although no pediatric speciﬁc studies have examined
MGMT status in GSCs, several adult studies have demonstrated
that GSCs have high levels of MGMT and more efﬁciently
repair DNA than non-GSC tumor cells (Liu et al., 2006; Pis-
tollato et al., 2010). While MGMT is an important factor for
temozolomide resistance in pediatric GBM, it is not an exclu-
sive mechanism as an MGMT-independent mechanism has been
identiﬁed. In a pediatric GBM cell line which was resistant to
temozolomide in the absence of MGMT, Gaspar et al. (2010)
discovered a PI3-K-mediated HOX/stem cell resistance gene sig-
nature. The resistant cell line was highly enriched for CD133 and
revealed an up-regulation of HOX gene expression. Resistance
to temozolomide was reversed with PI3-K pathway inhibition.
Importantly, they showed a correlation between HOXA9/HOXA10
gene expression in pediatricHGG samples and shorter patient sur-
vival. In embryonic development, HOX genes are critical for axis
determination, and a differential expression of HOX genes has
been found in neoplastic versus non-neoplastic human astrocytes
(Abdel-Fattah et al., 2006). The exact mechanism by which HOX
genes promote resistance to temozolomide is unclear, however it
may be through an anti-apoptotic, pro-proliferative mechanism
(Costa et al., 2010).
Pediatric GSCs are able to resist radiation damage by pref-
erential activation of the DNA damage response (Bao et al.,
2006a). Bao et al. (2006a) showed that the CD133+ fraction in
D456MG, a pediatric GBM, was enriched after radiation, and
the CD133+ GSCs survived radiation by more effectively repair-
ing radiation-induced DNA damage compared to CD133− cells.
The radioresistance of the GSCs was reversed by inhibiting Chk1
and Chk2 checkpoint kinases. The adhesion molecule L1CAM
(CD171) augmented the DNA damage checkpoint activation
which increased radioresistance of GSCs by enhancing Chk2 sig-
naling (Cheng et al., 2011). Due to the resistance of GSCs to
conventional therapeutics and their role in tumor initiation,main-
tenance, metastasis, and recurrence, novel targeted agents that
effectively kill GSCs are needed.
TARGETING GLIOMA STEM CELLS
Strategies to target GSCs include direct attacks such as targeting
unique biomarkers, blocking speciﬁc functions of GSCs, reversing
or overcoming resistancemechanisms, or inducing differentiation;
or indirect attacks at the GSC microenvironment (Binello and
Germano, 2011; Friedman and Gillespie, 2011). The usefulness of
an antibody targeted to a GSC marker depends on the speciﬁcity
of that marker. While there are a wide variety of surface, cyto-
plasmic, and nuclear markers attributed to GSCs (Table 1), these
markers are also found in normal cells. CD133, the most com-
monly used GSC maker, is expressed in neural, hematopoietic,
and endothelial cells. Moreover, CD133 may not mark all GSCs
and its expression is transilient making it a potentially less useful
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target. Newer GSC-speciﬁc biomarkers are needed which can be
used for directed immune therapies and vaccinations,monoclonal
antibodies, or small molecule inhibitors. Targeting speciﬁc func-
tions of GSCs such as growth factors, developmental and signaling
pathways and immune pathways is another promising approach
(Binello and Germano, 2011). Various inhibitors have been or are
being developed and tested, although there are a lack of studies
in pediatric GBM models. Successful targeting of these pathways
requires a comprehensive understanding of the regulators of each
pathway, the interactions between pathways, and the role of these
pathways in normal neural stem cell development.
As mechanisms by which pediatric GSCs resist traditional
therapies are uncovered, they can be targeted to overcome that
resistance or newer agents can be designed to militate against
resistance mechanisms. Approaches include blocking DNA repair
mechanisms such as disrupting the checkpoint response or tar-
geting MGMT; or down-regulating various pathways, multi-drug
resistance genes, or drug transporters involved in resistance. An
alternative method is to induce differentiation of GSCs to tumor
cells that are less tumorigenic and more sensitive to standard
therapies. Isotretinoin is an example of this approach which has
been used successfully in pediatric neuroblastoma patients and is
currently undergoing a trial in children with medulloblastoma.
In preclinical studies, retinoic acid differentiated GSCs, however
obtaining terminal differentiation was not uniformly seen (Karsy
et al., 2010; Niu et al., 2010).
Directly attacking GSCs may be limited by similarities of GSCs
to normal neural stem cells as well as by the genomic instability of
GSCs that may change their identity as a tumor progresses, there-
fore an alternative approach is indirectly targeting the GSC niche
(LaBarge, 2010). This, too, poses many obstacles. The GSC niche
must be distinct from the normal neural stem cell microenviron-
ment to avoid damaging critical cells for normal tissue repair and
maintenance. Furthermore, the niche may be unique in differ-
ent areas of a tumor, in distant tumor sites, or in different stages
of tumor progression requiring multiple approaches. In order to
effectively target the GSC niche, an improved understanding of
the residents and regulators of the niche is critical. Current meth-
ods to indirectly attack the GSC microenvironment include agents
that target angiogenesis, the physiologic hypoxia experienced by
HGG cells, or immune mediators of the niche (Binello and Ger-
mano,2011). Fewof these approaches have been tested in pediatric
HGG models. Bao et al. (2006b) demonstrated that the anti-
VEGF drug bevacizumab eliminated the proangiogenic effects
of pediatric GSCs on endothelial cells and suppressed growth of
GSC-derived xenografts. Bevacizumab is currently being studied
in combination with temozolomide as adjuvant to surgical resec-
tion and radiation in children with GBM through the Children’s
Oncology Group study ACNS0822. Alternatively, normal neural,
mesenchymal, or embryonic stem cells that are attracted to the
GSC microenvironment may be used as vehicles for delivery of
various therapies such as cytokines, enzymes, or enzyme/prodrug
suicide combinations to disrupt the niche and kill GSCs (Binello
and Germano, 2012). No speciﬁc studies have examined these
vehicles in pediatric GSCs, however human adipose mesenchymal
stem cells that produce tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) prolonged survival in animals with
brainstem gliomas suggesting this may be a useful approach to
treat DIPGs (Choi et al., 2011).
Another innovative promising approach to eradicate resistant
pediatric GSCs is oncolytic virotherapy, which can be utilized
to attack GSCs both directly and indirectly while sparing nor-
mal cells thereby limiting toxicities (Cripe et al., 2009; Friedman
et al., 2012b). The direct mechanism of killing involves a virus
infecting, replicating within, and lysing a GSC and then spread-
ing to nearby cells. Candidate viruses either normally do not
cause human disease but replicate in GSCs with altered signal-
ing pathways or deﬁcient interferon responses, or they contain
mutations that prevent the virus from infecting or replicating in
normal cells but permit infection and replication in GSCs. Large
DNA viruses which contain many non-essential genes may be
engineered to express therapeutic foreign gene products that can
either directly target GSCs or indirectly target the GSC microenvi-
ronment. Genetically engineered oncolytic herpes simplex virus-1
(oHSV) is one such candidate virus that has effectively targeted
GSCs directly and indirectly.
ENGINEERED ONCOLYTIC HERPES SIMPLEX VIRUS
ADVANTAGES AS A VIROTHERAPEUTIC AGENT
Oncolytic HSV offers several advantages as a virotherapeutic agent
to target GSCs and pediatricHGGs. Herpes simplex virus-1 (HSV-
1) is an enveloped, double-stranded (ds) DNA virus that does not
integrate into the host cell DNA. The virus undergoes a cytolytic
cycle which confers its oncolytic properties and this process is not
cell cycle-dependent like traditional therapies. Thus, oHSV is able
to evade many of the typical mechanisms that GSCs use to avoid
killing by chemotherapy and radiation. This cycle initially involves
cell entry via outer viral envelope glycoproteins B and C which
facilitate the binding of glycoprotein D to one of several entry
receptors including nectin-1 (CD111), nectin-2 (CD112), HVEM,
and modiﬁed heparan sulfate proteoglycan (Spear, 2004). Once
internalized, HSV moves to the cell nucleus where gene transcrip-
tion occurs in a temporal fashion consisting of intermediate-early
genes, followed by early genes and then late genes. The immediate-
early proteins regulate expression of early genes, which encode
enzymes necessary for viral DNA replication, and late genes,
which encode proteins that form the structural proteins of the
virion (Grandi et al., 2009). The envelope is derived by budding
through the nuclearmembrane of the cell, and the replication cycle
ends with viral particles lysing the cell and spreading to nearby
cells.
The HSV-1 genome is large (89 genes, 152 kb), and approxi-
mately 30 kb is“non-essential” for replication in cell culture. These
geneswhile dispensable are important in viral pathogenesis in vivo.
For the purposes of oHSV therapeutics, these non-essential genes
can be replaced with foreign DNA for gene therapy to augment
the oncolytic effect of the virus without compromising the virus’
ability to infect and replicate in glioma cells (Shah et al., 2003).
Importantly, deletion of certain HSV genes (e.g., the γ134.5 neu-
rovirulence gene) facilitates selective replication in glioma cells
(Chou et al., 1990; Markert et al., 1993). In the unlikely event that
a mutant virus produces toxicity in normal brain tissue, effec-
tive antiviral agents are clinically available. Glial tumors are ideal
targets for oHSV because the virus is neurotropic.
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CLINICAL USE AND SAFETY
Two viruses, G207 and HSV1716, have been safely injected intrac-
erebrally in several phase I trials in adults with recurrent HGGs
(seeTable 2 for a summary of viruses discussed in the text;Markert
et al., 2000, 2009; Rampling et al., 2000; Papanastassiou et al., 2002;
Harrow et al., 2004). G207 was derived from wild-type isolate
HSV-1(F) strain. It contains deletions in both copies of the γ134.5
gene and a LacZ gene insertion (which encodes β-galactosidase)
into theUL39 locus therebydisabling expressionof ICP6, the heavy
chain for viral ribonucleotide reductase (RR; Mineta et al., 1995).
The γ134.5 gene encodes the 263 amino acid infected cell protein
34.5 (ICP34.5) which has two critical functions: (1) it is essen-
tial for HSV-1 neurovirulence enabling it to infect and replicate in
neural cells, and (2) it enables the virus to overcome a cell’s normal
host defense mechanism against infection. Importantly, its dele-
tion also removes the opposite strand which encodes a portion of
the latency-activated transcripts (LAT) making the γ134.5-deleted
HSVs less capable of establishing and/or reactivating from latency
(Chou et al., 1990; Whitley et al., 1993; He et al., 1997).
Herpes simplex virus infection leads to the production of non-
host molecules that trigger a host-mediated antiviral response.
The best characterized of these is the dsRNA-activated protein
Table 2 | Summary of oncolytic HSVs discussed in the text.
Virus Deletions Foreign gene/promoter insertion Reference
34.5ENVE Deletions in γ134.5 gene and in-frame
gene-disrupting insertion of GFP within ICP6
gene
Vasculostatin (Vstat120) under control of the
HSV IE 4/5 promoter and ICP34.5 under
control of a synthetic nestin promoter
Yoo et al. (2012)
C134 Deletions in both copies of γ134.5 gene IRS1 gene under control of an HCMV
immediate early promoter
Shah et al. (2007)
Cassady et al. (2009)
G47Δ-mAngio Deletions of the γ134.5 and α47 genes and a
disabling lacZ insertion within ICP6 gene
Murine angiostatin Zhang et al. (2012)
G207 Deletions in both copies of γ134.5 gene and
disabling lacZ insertion within ICP6 gene
None Hunter et al. (1999),
Markert et al. (2000, 2009)
HSV1716 Deletions in both copies of γ134.5 gene None Rampling et al. (2000),
Papanastassiou et al. (2002),
Harrow et al. (2004)
M002 Deletions in both copies of γ134.5 gene Murine IL-12 under the transcriptional control
of the murine early-growth response-1
promoter (Egr-1)
Parker et al. (2000),
Markert et al. (2012)
M032 Deletions in both copies of γ134.5 gene Human IL-12 under the transcriptional control
of the murine early-growth response-1
promoter (Egr-1)
Markert et al. (2012)
MG18L disabling lacZ insertion within ICP6 gene and
a deletion at US3
None Kanai et al. (2011)
OncoVexGM−CSF Complete deletions of the genes encoding
ICP34.5 andICP47
GM-CSF, CMV promoter Senzer et al. (2009)
OV-Chase Deletions in both copies of γ134.5 gene and
in-frame gene-disrupting insertion of GFP
within ICP6 gene
Chondroitinase ABC under control of the HSV
IE4/5 promoter
Dmitrieva et al. (2011)
RAMBO Deletions in both copies of γ134.5 gene and
in-frame gene-disrupting insertion of GFP
within ICP6 gene
Vasculostatin (Vstat120) under control of the
HSV IE 4/5 promoter
Hardcastle et al. (2010)
rQNestin34.5 Deletions in γ134.5 gene and in-frame
gene-disrupting insertion of GFP within ICP6
gene
ICP34.5 under control of a synthetic nestin
promoter
Kambara et al. (2005a),
Yoo et al. (2012)
VAE Deletions in both copies of γ134.5 gene Endostatin-angiostatin fusion gene insert Zhu et al. (2011)
Δ68H-6 Disabling lacZ insertion within ICP6 gene and
γ134.5 Beclin 1 binding domain deletion
None Kanai et al. (2012b)
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kinase R (PKR) translational arrest. After cell entry, HSV produces
dsRNA. Upon binding viral dsRNA transcripts, PKR autophos-
phorylates and selectively phosphorylates eukaryotic initiating
factor 2α (eIF-2α) which is essential for host protein translation
in the infected cell (Figure 1; Williams, 2001). In wild-type HSV
infection, the γ134.5 product ICP34.5 binds and redirects protein
phosphatase-1α which desphosphorylates eIF-2α and allows viral
protein synthesis (He et al., 1997). Oncolytic HSVs deleted for the
γ134.5 gene are unable to evade PKR-mediated translational arrest
thus limiting viral replication in normal cells containing a func-
tional PKRresponse (Shah et al.,2007). ActivatedPKRalso induces
activation of nuclear factor-κB (NF-κB) which may contribute
to antiviral responses (Taddeo et al., 2003). Mutant viruses with
γ134.5-deletions may replicate in tumor cells which have defective
signaling pathways (e.g., defective PTEN and activated MAPK,
both of which can be present in HGG), or activating ras mutations
that results in defective PKR (Farassati et al., 2001; Smith et al.,
2006). Both EGFR and PDGFR signaling, which are constitutively
active in some pediatric HGGs, are known activators of ras (Sch-
lessinger, 2000; Paugh et al., 2010; Zarghooni et al., 2010; Steelman
et al., 2011).
The lacZ insertion adds additional protection for normal cells
becauseRR is vital for nucleotide synthesis necessary for viral repli-
cation and mutants are hypersensitive to acyclovir (Goldstein and
Weller, 1988; Coen et al., 1989). The insertion is less disruptive to
virus replication in dividing cancer cells which can provide cellular
RR for viral replication. Similar to G207, HSV1716 contains dele-
tions in both copies of the γ134.5 gene (also identiﬁed as RL1);
FIGURE 1 | Cellular response of normal cells and tumor cells to
infection with γ134.5-deleted HSV. In response to viral dsRNA and
interferon signaling, an intact PKR response in normal cells inhibits protein
synthesis and consequently late viral gene expression by phosphorylation of
eukaryotic initiating factor 2γ (eIF-2γ) and induces an antiviral response by
activation of NFκB. However, in tumor cells, the PKR mediated response is
blunted which results in late viral gene expression and reduced activation
of the antiviral immune response. This results in production of viral progeny
and expression of any added foreign genes. Resultant viral particles lyse the
cell and spread to nearby tumor cells. Expression of foreign genes can be
used to modulate the immune response or inhibit the microenvironment and
tumor growth.
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however HSV1716 was derived from wild-type strain 17 which
is a temperature insensitive isolate unlike the parental HSV-1(F)
strain for G207 (MacLean et al., 1991). HSV1716 virulence is
greater than that of G207 based on murine studies and the max-
imum safe dose [105 PFU (plaque-forming unit) for 1716 vs.
3 × 109 PFU for G207] used in clinical trials (Chambers et al.,
1995; McKie et al., 1998).
G207 safety has been conﬁrmed in both murine and non-
human primate studies using New World owl monkeys (Aotus
nancymaae) as young as 1-year old (Hunter et al., 1999). Owlmon-
keys are exquisitely sensitive to wild-type HSV-1 similar to human
infants, and in the primate studies, inoculation with 1 × 103 PFU
of wild-type HSV-1(F) caused rapid mortality. In contrast, intrac-
erebral inoculation with up to 1 × 109 PFU of G207 (equivalent to
a human dose of 5 × 1010 PFU) resulted in no short- or long-term
clinical complications. Similarly, direct right frontal lobe inocula-
tion in A. nancymaae of a γ134.5-deleted HSV-1 M002, which has
a foreign gene insert that expresses murine interleukin-12 (IL-12)
in physiologic amounts, resulted in no clinical or magnetic reso-
nance imaging (MRI) toxicity or histopathologic abnormalities at
1 month and 5.5 years after injection (Markert et al., 2012). These
studies strongly suggest that γ134.5-deleted viruses would be safe
in children.
In a study by Radbill et al. (2007), neonatal mice at post-
natal day 4 were injected intracerebrally with 2 μl of saline or
1 × 105 PFU of G207. No difference was seen between the
two groups in long-term physical development, cognitive per-
formance, or exploratory behaviors suggesting the virus had no
deleterious effect on neurodevelopment or brain function. The
only abnormality seen was histological and MRI evidence of uni-
lateral ventriculomegaly ipsilateral to the injection site in some of
the G207-treated mice and in one saline-injected mouse that was
attributed most likely to free-hand injection resulting in intraven-
tricular delivery of the virus. The authors concluded that an initial
study in children should exclude patients with intraventricular
tumors and children under 2.
In the ﬁrst adult clinical trial, G207 was proven safe with direct
stereotactic inoculation of up to 3 × 109 PFU of virus in up to
ﬁve loci within enhancing portions of recurrent HGGs (Mark-
ert et al., 2000). There were no serious adverse events attributable
to the virus, and therefore a maximum tolerated dose was not
reached. A follow-up phase Ib study in adults with recurrent
HGGs, likewise demonstrated safety of two separate stereotactic
injections of G207 (total dose 1.15 × 109; Markert et al., 2009).
One dose was administered 2–5 days prior to resection and a
second dose was subsequently given immediately after resection
into the surrounding tumor cavity. While the studies were only
designed to determine safety and not efﬁcacy, responses were
seen in a number of patients including two long-term survivors
for >5.5 years. Patients with recurrent HGGs only live a few
months on average. A third phase I trial of G207 injected into
recurrent HGGs in ﬁve loci followed by a single 5 Gray frac-
tion of ionizing radiation completed accrual and will be reported
shortly. Low-dose radiation enhanced oHSV replication and efﬁ-
cacy in a preclinical HGG model suggesting the approach used
in the trial may result in improved efﬁcacy (Advani et al., 2011).
This enhancement appears to be through multiple mechanisms
including inhibition of radiation-induced DNA repair by HSV
protein ICP0, up-regulation of cellular genes like RR that com-
plement viral gene deletions, and greater activation of viral late
promoters through thep38mitogen-activatedprotein kinase path-
way (Stanziale et al., 2002; Hadjipanayis andDeLuca, 2005; Mezhir
et al., 2005).
Clinical trials of HSV1716 in HGG patients likewise demon-
strated safety of the virus with inoculation intratumorally or into
the tumor cavity (Rampling et al., 2000; Papanastassiou et al.,
2002; Harrow et al., 2004). An antiviral immune response was
documented in several patients, and no toxicity was seen in HSV-
seronegative (or sero-positive) patients. Due to the more virulent
nature of this HSV seen in mice, the highest dose examined was
1× 105 PFU. Importantly, like in theG207 trials, clinical responses
were seen which resulted in several long-term survivors. While
neither virus has been used in children with HGGs, HSV1716 is
currently being used in a phase I trial in children older than 6 with
recurrent solid tumors outside the central nervous system (Clin-
icalTrials.gov identiﬁer: NCT00931931). The results of the G207
and HSV1716 trials indicate that further development of oHSV
for the treatment of HGGs in both adults and children would be a
worthwhile endeavor.
oHSV TARGETING OF PEDIATRIC GSCs
For oHSV to have long-term efﬁcacy in treating pediatric HGGs,
the virus must be able to target and kill chemo- and radiation-
resistant GSCs. GSCs have the ability to migrate through adjacent
normal brain tissue, and this likely explains why many tumors
recur directly outside the margins of radiotherapy. Thus, delivery
and spread of oHSV is critical to target GSCs. Optimal deliv-
ery of oHSV to target dispersing GSCs remains to be deﬁned.
Intracerebral administration has been utilized to allow for direct
inoculation of virus into the enhancing portions of a tumor or
tumor bed by one or more passages of a stereotactically inserted
needle or by passage of several neurosurgical catheters that have
multiple openings near the tip followed by slow infusion by con-
vection enhanced delivery over 6–12 h. The latter approach ismore
likely to provide a broader distribution of the virus. Theoretically,
the infectious viral particles are small enough (150–200 nm) to
percolate through the interstitial spaces in edematous brain, car-
ried by convection of the transudate and CSF accumulating in the
peritumoral spaces.
Another approach is systemic delivery of the virus; however
this method is potentially complicated by the blood–brain bar-
rier and HSV-1 seropositivity of the majority of adult humans
which results in circulating antibodies that may deplete a signif-
icant amount of the intravenous dose. Since fewer children are
sero-positive for HSV-1 (<20% positive in children under 4 and
approximately 36% by age 13), children may be better candidate
than adults for systemic therapy (Xu et al., 2007; Friedman et al.,
2009b). The blood–brain barrier canbe disrupted by osmotic solu-
tions like mannitol or the inﬂammatory mediator bradykinin to
permit intracarotid or intra-arterial injections of oHSV to target
gliomas (Rainov et al., 1995; Liu et al., 2005). Other novel meth-
ods to delivery oHSV to brain tumors such as the use of carrier
vehicles with inherent migratory and tumor tropic properties are
currently being explored (Brown et al., 2003).
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After an oHSV is delivered to a GSC, it must be able to enter
the cell to kill it directly. While there are several entry receptors,
nectin-1 (CD111) is the most efﬁcient entry receptor for HSV-1
and has been shown to at least partially contribute to the variabil-
ity in infectability of HGGs (Krummenacher et al., 2004; Rueger
et al., 2005). We demonstrated that oHSV was unable to effectively
enter and infect gliomaxenograft cellswith<20%nectin-1 expres-
sion (Friedman et al., 2009a). CD133+ GSCs expressed nectin-1 in
similar amounts to CD133− tumor cells in most GBM xenografts
tested, including the pediatric GBM xenograft D456MG, which
expressed high levels of nectin-1, suggesting that oHSV should
be able to enter and infect GSCs and tumor cells equally. This
was conﬁrmed with cytotoxicity testing in vitro; the lethal dose
required to kill 50% (LD50) of CD133+ or CD133− D456MG
cells was not signiﬁcantly different, and D456MG, including the
GSCs, were more sensitive to killing by G207 and M002 than six
adult GBM xenografts tested (Cassady et al., 2009; Friedman and
Gillespie, 2011). Athymic nude mice with D456MG implanted
intracranially lived signiﬁcantly longer after a single injection of
the oHSV C134, a chimeric γ134.5-deleted virus with the human
cytomegalovirus (HCMV) IRS1 gene under control of the HCMV
immediate early promoter; this insertion improves viral replica-
tion without restoring neurovirulence (Shah et al., 2007; Cassady
et al., 2009). About 30% of the C134-treated mice were long-term
survivors, suggesting that the GSC fraction was eradicated.
Interestingly, when GBM xenograft cells including D456MG
were grown in 1% hypoxia to simulate the more severe physiologic
hypoxic environment that glioma cells experience in vivo, nectin-1
expression increased signiﬁcantly (12% increase in D456MG cells;
Friedman et al., 2012a). Nectin-1 is an adhesion molecule and
may be up-regulated in hypoxia to increase adhesion to vascu-
lar endothelial cells and facilitate tumor angiogenesis (Koike et al.,
2004). Despite the increase in nectin-1, γ134.5-deleted virus infec-
tivity, replication, and cytotoxicity were signiﬁcantly diminished
in the pediatric GBM xenograft model under hypoxia. This sug-
gests that other cellular factors can limit oHSV even if there are
ample entry molecules.
The decreased efﬁcacy of a γ134.5-deleted virus in physio-
logic hypoxic conditions is not inconsequential. As discussed
earlier, hypoxia is a key regulator of GSCs by promoting the
GSC-phenotype which supports GBM development, aggressive-
ness, angiogenesis, and resistance to chemotherapy and radiation
(Jensen, 2009). While hypoxia signiﬁcantly increased the CD133+
fraction in D456MG by nearly fourfold and decreased the percent-
age of CD133+ GSC infected, there was not a signiﬁcant difference
in the percentage of CD133+ cells infected compared to all tumor
cells in normoxia or hypoxia suggesting that theCD133+ cells were
not inherently more resistant (Figure 2; Friedman et al., 2012a).
Nevertheless, a better understanding of the mechanism(s) behind
the reduced γ134.5-deleted virus efﬁcacy in hypoxia is needed.
Potential causes include reduced viral entry or transport, enhanced
antiviral host cell responses, or increased autophagy limiting viral
egress in hypoxia.
FUTURE STRATEGIES FOR oHSV TARGETING OF PEDIATRIC GSCs
AsGSCbiology is being revealed, next-generation viruses are being
developed and tested todirectly and indirectly targetGSCs through
FIGURE 2 | Percentage of pediatric D456MG cells infected in normoxia
and hypoxia by a γ134.5-deleted virus 30 h after infection. Cells were
infected at 10 PFU/cell by a GFP-expressing γ134.5-deleted virus for 30 h.
After the addition of a CD133 allophycocyanin (APC) labeled antibody, cells
were analyzed by ﬂuorescent activated cell sorting (FACS) analysis looking
for GFP and APC expression. There was a signiﬁcant decrease in infectivity
seen in all cells and CD133+ cells in hypoxia compared to normoxia but a
similar number of CD133+ cells were infected compared to all cells in each
environment suggesting CD133+ cells were not more resistant.
transcriptional or novel receptor targeting. Several approaches are
being evaluated including retargeting the virus to infect GSCs;
enhancing the efﬁcacy of the virus by improving viral replication,
harnessing the immune system, or attacking the GSC microenvi-
ronment; or combining oHSV with traditional therapies, small
molecule inhibitors, or potentially other oncolytic viruses. As
an example of transcriptional targeting, Kambara et al. (2005a)
designed rQNestin34.5 which expresses ICP34.5 under control
of a synthetic nestin promoter. As previously discussed, nestin
is an intermediate ﬁlament protein expressed in GSC as well as
embryonic and normal neural stem cells found in the subependy-
mal zone in the brain, but it is not present in normal human
astrocytes. While not tested speciﬁcally in GSCs, the virus pro-
longed survival in glioma-bearing mice. Whether or not this virus
would also be able to replicate in normal neural stem cells is not
clear.
Targeting other proteins that could serve as potential entry
molecules that are speciﬁc for tumor cells but poorly expressed
or not expressed in normal cells, Zhou and Roizman (2006) have
devised a strategy of deleting the key recognition unit of glyco-
protein D for CD111 and HVEM, but preserving the membrane
fusion activity to allow virus entry. Inclusion of ligands for IL13-
receptor α2 and urokinase plasminogen activator receptor has
been shown to permit oHSV binding and entry into cells (Zhou
et al., 2002; Zhou and Roizman, 2005; Kamiyama et al., 2006).
Campadelli-Fiume and colleagues have exploited related strate-
gies to insert a single chain antibody to bind Her2/neu (Lollini
et al., 2009; Menotti et al., 2009; Gambini et al., 2012). Uchida
et al. (2012) described another approach at retargeting oHSV by
eliminating the natural receptor-binding activities of glycoprotein
D; introducing single-chain antibodies speciﬁc for EGFR, which
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is overexpressed in many gliomas; and adding entry-accelerating
mutations to glycoprotein B into a detargeted mutant form of gly-
coprotein D. The novel virus entered through EGFR and achieved
infection similarly to wild-type virus while prolonging survival
in mice with orthotopic primary human GBM xenografts. These
studies highlight how oHSV may be used to speciﬁcally target
GSCs.
While γ134.5-deleted viruses can replicate inHGGs, replication
is attenuated compared to wild-type HSV-1. Newer viruses have
been designed which improve viral replication to achieve greater
viral titers and to sustain infection longer in order to increase
tumor cell transduction. The chimeric γ134.5-deleted virus C134
restores one of the critical ICP34.5 functions of evading the host
PKR antiviral response through production of HCMV IRS1 (Cas-
sady, 2005). By restoring this function, late viral protein synthesis
is augmented and higher viral titers are achieved in glioma cells
without restoring neurovirulence. Compared to its parent γ134.5-
deleted virus, C134 was superior at improving survival in animals
with gliomas (Shah et al., 2007). The virus is also very effective
at killing D456MG GSCs (Cassady et al., 2009). C134 has been
produced in clinical-grade for an upcoming trial in adults with
recurrent HGGs, and a future pediatric trial is possible.
Autophagy, a catabolic process which involves the recycling
of cellular contents and may lead to cellular self-degradation,
plays an important role in the health of post-mitotic neuronal
cells and in antiviral innate immunity by limiting viral produc-
tion and thus spread to nearby cells (Orvedahl and Levine, 2008).
Viral-induced PKR initiates autophagy through eIF-2α phospho-
rylation. Recent research suggests ICP34.5 confers neurovirulence
by inhibiting autophagy through beclin-1 (Orvedahl et al., 2007).
Kanai et al. (2012b) developed Δ68H-6, an ICP6 mutant with the
γ134.5 gene intact except for the Beclin-1 binding domain. The
mutant virus was minimally neuropathogenic but replicated well
inGSCs in vitro and prolonged survival inmice bearing orthotopic
gliomas. These studies suggest that autophagy-related genes may
be effectively manipulated to improve viral replication.
Another strategywhichmay improve the targeting of GSCs is to
enhance the directed attack of the virus by employing the immune
system. In addition to the attenuated replication of γ134.5-deleted
mutants, the tumoral environment of highly necrotic and inﬁltra-
tive HGGs may limit the virus’ ability to infect all GSCs. One way
to augment the antitumor effect of the virus is through cytokine
production. In this model, the virus infects a GSC, replicates,
and produces a cytokine of interest which attracts immune effec-
tor cells. The infected GSC is lysed by the virus which exposes
GSC-speciﬁc antigens to the effector cells. This activates an anti-
tumor immune response that leads to elimination of non-infected
GSCs and tumor cells. Because effector cells may also eliminate
the virus thus impeding its oncolytic effects, elucidating the right
balance between virus replication and an antitumor response is
likely critical (Alvarez-Breckenridge et al., 2012).
An example of a cytokine producing virus is M002. The virus
produces physiologic relevant amounts of IL-12. IL-12 stimulates
gamma interferon production from NK cells and T cells which
activates cytotoxic T lymphocyte and Th1 cells. In addition, IL-12
promotes antiangiogenesis against tumor vasculature through NK
cell activation and subsequent cytokine secretion (Parker et al.,
2000; Hellums et al., 2005; Markert et al., 2012). In preclinical
studies, M002 was safe and more efﬁcacious than G207 and read-
ily killed GSCs in a pediatric GBM model (Friedman et al., 2009a;
Markert et al., 2012). The humanized IL-12 version of the virus,
M032, has been produced in clinical-grade and a trial in adults
with recurrent HGGs is forthcoming. Once safety in adults is con-
ﬁrmed, a pediatric trial will follow. A similar immune-enhanced
34.5-deleted virus, OncoVexGM−CSF, which produces clinically
relevant amounts of granulocyte-macrophage colony-stimulating
factor, showed efﬁcacy in injected and uninjected lesions in some
patients with unresectable metastatic melanoma and is currently
being investigated in a phase III study (Senzer et al., 2009).
Indirectly targeting the GSC niche with oHSV gene therapy is
another promising approach. Several unique viruses have recently
been developed and tested preclinically, although none have been
speciﬁcally tested in pediatric HGG models. The γ134.5-deleted
oHSV OV-Chase expresses chondroitinase ABC (Chase-ABC),
a bacterial enzyme that removes the chondroitin sulfate from
proteoglycans which are major constituents of the extracellular
matrix of HGGs (Dmitrieva et al., 2011). Compared to its par-
ent virus without Chase-ABC, OV-Chase signiﬁcantly enhanced
spread in glioma spheroids and prolonged survival in animals with
intracranial glioma xenografts.
Several viruses which target angiogenesis have been evaluated.
RAMBO (rapid antiangiogenesis-mediated by oncolytic virus)
expresses vasculostatin (VStat120), the cleaved and secreted extra-
cellular fragment of brain-speciﬁc angiogenesis inhibitor 1 (BAI1;
Hardcastle et al., 2010). The virus inhibited glioma growth in
mice and had an antiangiogenic effect as measured by a reduced
tumor vascular volume fraction and microvessel density. A sim-
ilar virus that expresses VStat120, 34.5ENVE, was created within
the backbone of rQNestin34.5 and likewise prolonged survival
in glioma-bearing mice and showed evidence of antiangiogenesis
with reduced microvessel density and increased tumoral necrosis
compared to a control virus (Yoo et al., 2012). Two angiostatin-
based γ134.5-deleted oHSVs have effectively targeted gliomas and
GSCs. VAE carries an exogenous endo-angio fusion gene and
produces the potent angiogenesis inhibitors endostatin and angio-
statin (Zhu et al., 2011). Similar to the control virus, VAE-infected
GSCs and signiﬁcantly inhibited their viability and ability to self-
renew. The fusion-gene was expressed in GSCs within 48 h after
infection, and the semi-puriﬁed virally produced fusion protein
reduced proliferation of brain microvascular endothelial cells in
vitro, conﬁrming the activity of the constituent proteins. Simi-
larly, G47Δ-mAngio expresses angiostatin, and in combination
with the VEGF inhibitor bevacizumab, the virus increased glioma
tumor lysis and angiostatin-mediated inhibition of VEGF leading
to a decreased invasive tumor phenotype (Zhang et al., 2012).
Similar to how combination chemotherapy strategies that
use agents with different mechanisms of attack have enhanced
tumor cell killing and decreased tumor resistance, combination
approacheswith oHSV and traditional therapies or smallmolecule
inhibitors may improve outcomes and permit lower doses of
toxic chemotherapeutics and radiation. This would limit toxi-
cities, which is vital for potential use in the developing brain
of a child. As previously discussed, low-dose radiation has been
demonstrated to enhance oHSV replication (Advani et al., 2011).
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Recent studies have shown that temozolomide or low-dose etopo-
side and oHSV acted synergistically in killing GSCs (Cheema et al.,
2011; Kanai et al., 2012a). The addition of cyclophosphamide
to rQNEstin34.5 enabled lower doses of the virus to be used to
achieve improved animal survival (Kambara et al., 2005b). Such
combination strategies may allow for more virulent viruses to
be used safely. New monoclonal antibodies and small molecule
inhibitors may complement oHSV by augmenting viral replica-
tion, altering key regulatory pathways, and increasing apoptosis.
MG18L, an oHSV with ICP6 disabled and deletion in Us3, which
encodes a serine-threonine kinase with multiple functions includ-
ing inhibition of virus-induced apoptosis and activation of Akt,
acted synergistically with PI3-K/Akt inhibitors to target GSCs
effectively (Kanai et al., 2011). There are an abundance of new
antibodies and small molecule inhibitors that require testing in
combination with oHSV.
CONCLUDING REMARKS
Outcomes for children with HGGs remain poor with minimal
improvement in overall survival rates seen over the past 30 years,
and current therapies are extremely toxic to the developing brain.
The difﬁculty in curing children with HGGs is likely due to a
chemotherapy and radiation-resistant population of cells that play
an integral role in tumor initiation, proliferation, invasiveness, and
aggressiveness. These GSCs are maintained by a variety of signal-
ing pathways and reside in a tightly regulated microenvironment.
Novel therapeutics which can target and kill GSCs are desperately
needed to improve outcomes and reduce morbidity in children
with HGGs.
oHSV, which can directly attack GSCs and directly and indi-
rectly target them through expression of various therapeutic
foreign genes, offers an innovative, safe approach. A variety of
strategies to enhance viral efﬁcacy are being developed such as
improving delivery methods, tumor speciﬁcity, and viral repli-
cation; minimizing viral clearance and antiviral defense mech-
anisms; increasing tumor-directed immune responses; and dis-
rupting the tumor microenvironment. Combining these various
strategies will likely result in more efﬁcacious viruses, and com-
bining oHSVwith radiation, various chemotherapeutics including
monoclonal antibodies and small molecule inhibitors, and possi-
bly even other viruses with different mechanisms of attack will
likely provide a synergistic effect. Through these various com-
bination approaches, oHSV has great potential to target resistant
GSCs thereby improvingoutcomes andquality of life bydecreasing
toxicity for children with HGGs.
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